Patents by Inventor Mark Peter Ridgill

Mark Peter Ridgill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Alkenyl-substituted spirocyclic sulfamides as inhibitors of gamma-secretase
    Patent number: 7371771
    Abstract: Compounds of formula (I) are disclosed: wherein R4 is an alkenyl group of defined structure. The compounds inhibit gamma-secretase, and hence are useful for treatment of Alzheimer's disease.
    Type: Grant
    Filed: April 24, 2003
    Date of Patent: May 13, 2008
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Jose Luis Castro Pineiro, Joanne Claire Hannam, Timothy Harrison, Andrew Madin, Mark Peter Ridgill
  • Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase
    Patent number: 7282513
    Abstract: Compounds of formula I are disclosed: in which X is a 5-membered heteroaryl ring and R is as defined herein. The compounds are inhibitors of the processing of APP by gamma-secretase, and hence are useful in the treatment or prevention of Alzheimer's disease.
    Type: Grant
    Filed: March 2, 2006
    Date of Patent: October 16, 2007
    Assignee: Merck Sharp & Dohme Limited
    Inventors: Ian James Collins, Laura Catherine Cooper, Timothy Harrison, Linda Elizabeth Keown, Andrew Madin, Mark Peter Ridgill
  • Sulfonamides, sulfamates and sulfamides as gamma-secretase inhibitors
    Patent number: 7144910
    Abstract: Compounds of formula I: inhibit the processing of APP by gamma-secretase, and hence are useful in treating or preventing Alzheimer's disease.
    Type: Grant
    Filed: October 29, 2003
    Date of Patent: December 5, 2006
    Assignee: Merck Sharp & Dohme Limited
    Inventors: Andrew Madin, Mark Peter Ridgill
  • Heteroaryl substituted spriocyclic sulfamides for inhibition of gamma secretase
    Patent number: 7041689
    Abstract: Compounds of formula I are disclosed: in which X is a 5-membered heteroaryl ring and R is as defined herein.
    Type: Grant
    Filed: April 24, 2003
    Date of Patent: May 9, 2006
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Ian James Collins, Laura Catherine Cooper, Timothy Harrison, Linda Elizabeth Keown, Andrew Madin, Mark Peter Ridgill
  • Alkynly-substituted spirocyclic sulfamides for the treatment of alzheimer's disease
    Patent number: 7041688
    Abstract: Compounds of formula (I) are disclosed.
    Type: Grant
    Filed: April 24, 2003
    Date of Patent: May 9, 2006
    Assignee: Merck Sharp & Dohme Lt.d.
    Inventors: Alister Campbell, Mark Peter Ridgill
  • 2-aryl indole derivatives and their use as therapeutic agents
    Publication number: 20010039286
    Abstract: The present invention relates compounds of the formula (I): 1
    Type: Application
    Filed: February 13, 2001
    Publication date: November 8, 2001
    Inventors: Kevin Dinnell, Jason Matthew Elliott, Gregory John Hollingworth, Mark Peter Ridgill, Duncan Edward Shaw
  • Tetrahydropyridine derivatives as dopamine receptor subtype ligands
    Patent number: 5861407
    Abstract: A class of substituted 1,2,3,6-tetrahydropyridine derivatives are disclosed that are ligands for dopamine receptor subtypes within the body. These compounds are therefore useful in the treatment and/or prevention of disorders of the dopamine system, in particular schizophrenia or depression.
    Type: Grant
    Filed: February 21, 1997
    Date of Patent: January 19, 1999
    Assignee: Merck Sharp & Dohme, Ltd.
    Inventors: Neil Roy Curtis, Janusz Jozef Kulagowski, Paul David Leeson, Ian Michael Mawer, Mark Peter Ridgill
  • Tetrahydropyridinylmethyl derivatives of pyrrolo?2,3-B!pyridine
    Patent number: 5830901
    Abstract: Disclosed is a class of pyrrolo?2,3-b!pyridine derivatives of formula (I) wherein Q represents a moiety of formula Qa or Qb, which are ligands for dopamine receptor subtypes within the body, in particular the dopamine D4 receptor subtype and are therefore useful in the treatment and/or prevention of disorders of the dopamine system, including schizophrenia.
    Type: Grant
    Filed: January 27, 1997
    Date of Patent: November 3, 1998
    Assignee: Merch Sharp & Dohme Ltd
    Inventors: Neil Roy Curtis, Janusz Jozef Kulagowski, Paul David Leeson, Mark Peter Ridgill
  • Indole derivatives as dopamine D4 antagonists
    Patent number: 5814644
    Abstract: Compound of formula (I), or a pharmaceutically acceptable salt thereof or a prodrug thereof wherein E represents --CH.sub.2 -- or --CH.sub.2 CH.sub.2 --; R represents hydrogen or C.sub.1-6 alkyl; Q represents a moiety of formula Qa, Qb, Qc or Qd which are antagonists of dopamine receptor subtypes within the brain, having a selective affinity for the dopamine D.sub.4 receptor subtype over other dopamine receptor subtypes, and are accordingly of benefit in the treatment and/or prevention of psychotic disorders such as schizophrenia whilst manifesting fewer side-effects than those associated with classical neuroleptic drugs.
    Type: Grant
    Filed: April 8, 1996
    Date of Patent: September 29, 1998
    Assignee: Merck Sharp & Dohme, Ltd.
    Inventors: Janusz Jozef Kulagowski, Paul David Leeson, Mark Peter Ridgill
  • Pyrrolo-pyridine derivatives
    Patent number: 5712285
    Abstract: A class of pyrrolo?2,3 -b!pyridine derivatives, linked via the 3-position thereof by a methylene group to a tetrahydropyridinyl moiety, the latter moiety being substituted in turn by an aryl- or heteroaryl-substituted divalent monocyclic radical, are ligands for dopamine receptorsubtypes within the body, in particular the D.sub.4 subtype, and are accordingly of use in the treatment and/or prevention of disorders of the dopamine system, including schizophrenia and depression.
    Type: Grant
    Filed: April 3, 1996
    Date of Patent: January 27, 1998
    Assignee: Merck, Sharp & Dohme, Ltd.
    Inventors: Neil Roy Curtis, Janusz Jozef Kulagowski, Paul David Leeson, Mark Peter Ridgill
  • Pyrrolo-pyridine derivatives
    Patent number: 5700809
    Abstract: Compounds of formula I are ligands for dopamine receptor subtypes within the body and are therefore useful in the treatment and/or prevention of disorders of the dopamine system, in particular schizophrenia.
    Type: Grant
    Filed: August 29, 1995
    Date of Patent: December 23, 1997
    Assignee: Merck Sharp & Dohme, Ltd.
    Inventors: Paul David Leeson, Adrian Leonard Smith, Mark Peter Ridgill, Raymond Baker, Neil Roy Curtis, Janusz Jozef Kulagowski